端粒酶在乳腺组织中的表达

目的：检测端粒酶在乳腺组织中的表达，探讨其在诊断和预后中的意义。方法：采用TRAP－ELISA方法，对109例乳腺癌、30例正常乳腺组织及囊性增生病、30例乳腺腺纤维瘤和10例乳腺癌前病变进行端粒酶活性检测。结果：正常乳腺组织及囊性增生病无端粒酶活性，乳腺腺纤维瘤有23．33％端粒酶呈弱表达，乳腺癌前病变有4例端粒酶表达。乳腺癌中88．07％可以检测到端粒酶活性，随着临床分期的增加，端粒酶阳性率不断上升。其中端粒酶阳性率在临床I期为64．29％，Ⅱ期及以上为91．58％（P＜0．05）。端粒酶阳性率在腋淋巴结转移阴性组中为75．56％，而转移阳性组中为96．88％（P＜0．01）。端粒酶表达在ER（－）组与ER（＋）组间无明显差别。端粒酶表达在PgR(-)为95．08％，在PgR( )组为79．17％（P＜0．01）。结论：正常乳腺组织中无端粒酶表达。从乳腺癌癌前病变至各期乳腺癌中，端粒酶表达逐渐上升，端粒酶激活可能是乳腺癌形成和发展中的关键步骤，可以为乳腺癌诊断提供重要依据，在其预后判断中有着重要作用。

Telomerase Activity in Human Breast Tissues

To detect the expression of ribonucleoprotein enzyme telomerases ,and explore its significance in diagnosis and prognosis.Methods:Telomerase acti vity was detected in 109 breast cancers,30 normal tissues and fibrocystic lesion s,30 fibroadenomas,and 10 precancerous lesions.Results:Telomerase activity was n ot detected in any 30 normal tissues and fibrocystic lesions,surprisingly low le vels of telomerase activity were detected by 23.33% in fibroadenomas.Among samp les of precancerous lesions,telomerase activity was detected by 40.00%. In PgR( -)and PgR(+)cancers, the activity was 95.08% and 79.17% respectively.Conclus ion:Telomerase reactivity is a hallmark in cancer form and developmet.Telomerase activity is a good biomarker for diagnosis.Since RNA component of telomerase is very shot,it can be used as a favorable target of gene therapy.